Last reviewed · How we verify
RTX-GRT7039
RTX-GRT7039 is a selective antagonist of the P2X3 receptor that reduces pain signaling by blocking ATP-mediated nociceptive transmission.
RTX-GRT7039 is a selective antagonist of the P2X3 receptor that reduces pain signaling by blocking ATP-mediated nociceptive transmission. Used for Chronic cough, Neuropathic pain.
At a glance
| Generic name | RTX-GRT7039 |
|---|---|
| Sponsor | Grünenthal GmbH |
| Drug class | P2X3 receptor antagonist |
| Target | P2X3 |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
P2X3 receptors are ion channels expressed on sensory neurons that mediate pain perception when activated by extracellular ATP. By selectively antagonizing P2X3, RTX-GRT7039 dampens pain signal transmission without affecting other purinergic pathways. This mechanism is particularly relevant for chronic pain conditions where ATP-driven nociception plays a significant role.
Approved indications
- Chronic cough
- Neuropathic pain
Common side effects
- Taste disturbance
- Dizziness
- Headache
Key clinical trials
- Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis (PHASE3)
- Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee (PHASE3)
- Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RTX-GRT7039 CI brief — competitive landscape report
- RTX-GRT7039 updates RSS · CI watch RSS
- Grünenthal GmbH portfolio CI